证券代码：300318 证券简称：博晖创新 公告编号：临 2024-003 北京博晖创新生物技术集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 北京博晖创新生物技术集团股份有限公司（以下简称"公司"）分别于2023年 4月25日、2023年6月29日召开第七届董事会第二十三次会议、2022年度股东大会， 审议通过了《关于2023年度担保额度预计的议案》，同意为公司控股子公司博晖 生物制药（河北）有限公司（以下简称"河北博晖"）、公司全资子公司博晖生 物制药（内蒙古）有限公司（以下简称"内蒙古博晖"）、公司控股子公司广东卫 伦生物制药有限公司（以下简称"广东卫伦"）提供银行等金融机构授信担保，担 保总金额不超过120,000万元；其中为河北博晖提供担保额度合计不超过40,000万 元、为内蒙古博晖提供担保额度合计不超过75,000万元、为广东卫伦提供担保额 度 合 计 不 超 过 5,000 万 元 。 详 见 公 司 于 2023 年 4 月 26 日 在 巨 潮 资 讯 网 （www.c ...

二、担保进展情况 证券代码：300318 证券简称：博晖创新 公告编号：临 2024-001 北京博晖创新生物技术集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 北京博晖创新生物技术集团股份有限公司（以下简称"公司"）分别于2023年 4月25日、2023年6月29日召开第七届董事会第二十三次会议、2022年度股东大会， 审议通过了《关于2023年度担保额度预计的议案》，同意为公司控股子公司博晖 生物制药（河北）有限公司（以下简称"河北博晖"）、公司全资子公司博晖生 物制药（内蒙古）有限公司（以下简称"内蒙古博晖"）、公司控股子公司广东卫 伦生物制药有限公司（以下简称"广东卫伦"）提供银行等金融机构授信担保，担 保总金额不超过120,000万元；其中为河北博晖提供担保额度合计不超过40,000万 元、为内蒙古博晖提供担保额度合计不超过75,000万元、为广东卫伦提供担保额 度 合 计 不 超 过 5,000 万 元 。 详 见 公 司 于 2023 年 4 月 26 日 在 巨 潮 资 讯 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-053 北京博晖创新生物技术集团股份有限公司 关于通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司 董 事 会 2023 年 12 月 1 日 北京博晖创新生物技术集团股份有限公司（以下简称"公司"）于近日收到北 京市科学技术委员会、北京市财政局、国家税务总局北京市税务局联合颁发的《高 新技术企业证书》，公司再次顺利通过了高新技术企业认定。具体情况如下： 证书编号：GR202311003124 发证时间：2023 年 10 月 26 日 有效期：三年 本次认定是公司原《高新技术企业证书》有效期满后的再次认定，根据《中 华人民共和国企业所得税法》和《高新技术企业认定管理办法》等有关规定，公 司再次通过高新技术企业认定后，自颁发证书之日起连续三年继续享受国家关于 高新技术企业的相关优惠政策，按 15%的税率征收企业所得税。公司 2023 年度 已适用 15％的税收优惠政策，故本次高新技术企业证书的再次认定不会对公司 2023 年经营业 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-052 生产单位：博晖生物制药（河北）有限公司； 法定代表人：崔卫东； 机构名称：罗平博晖单采血浆站； 主要负责人：朱弋黔； 地址：云南省曲靖市罗平县罗雄街道白龙潭综合物流园区（罗平四中对面）； 业务项目：原料血浆采集； 许可证号：云卫浆准字[2023]第 04 号； 北京博晖创新生物技术集团股份有限公司 关于控股子公司下属浆站取得单采血浆许可证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京博晖创新生物技术集团股份有限公司（以下简称"公司"）控股子 公司博晖生物制药（河北）有限公司下属罗平博晖单采血浆有限公司（以下简称 "罗平浆站"）取得云南省卫生健康委员会颁发的《单采血浆许可证》，罗平浆站 经核准登记，准予执业。主要信息如下： 有效期限：2023 年 11 月 21 日至 2025 年 11 月 20 日。 特此公告。 北京博晖创新生物技术集团股份有限公司 董 事 会 2023 年 11 月 23 日 采浆区域：罗平县行政区域内； ...

Report Overview [Important Notice](index=1&type=section&id=%E9%87%8D%E8%A6%81%E5%86%85%E5%AE%B9%E6%8F%90%E7%A4%BA) This report emphasizes the board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of information disclosure, and states that this quarterly report is unaudited - The board of directors, supervisory board, and directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, with no false records, misleading statements, or major omissions[3](index=3&type=chunk) - The company's head, chief accountant, and head of accounting department declare: ensuring the truthfulness, accuracy, and completeness of financial information in the quarterly report[3](index=3&type=chunk) - The company's third-quarter report is unaudited[4](index=4&type=chunk)[30](index=30&type=chunk) Major Financial Data [Key Accounting Data and Financial Indicators](index=2&type=section&id=%28%E4%B8%80%29%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company achieved significant growth in operating revenue and net profit for Q3 2023 and YTD, with net profit attributable to shareholders increasing over **135%**, and net cash flow from operating activities surging by **465.78%** 2023 Q3 and YTD Key Financial Indicators | Indicator | Current Period (Q3) | YoY Change in Current Period | YTD | YoY Change in YTD | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 279,191,923.62 | 30.40% | 806,104,920.39 | 34.93% | | Net Profit Attributable to Shareholders (CNY) | 8,211,628.53 | 142.03% | 14,137,166.03 | 135.96% | | Net Profit Attributable to Shareholders Excluding Non-recurring Gains/Losses (CNY) | 6,889,715.80 | 135.94% | 12,114,341.57 | 129.96% | | Net Cash Flow from Operating Activities (CNY) | -- | -- | 103,617,734.96 | 465.78% | | Basic Earnings Per Share (CNY/share) | 0.0101 | 142.26% | 0.0173 | 135.97% | | Diluted Earnings Per Share (CNY/share) | 0.0101 | 142.26% | 0.0173 | 135.97% | | Weighted Average Return on Net Assets | 0.58% | 1.94% | 1.01% | 5.13% | | Total Assets (CNY) | 3,872,849,081.89 | -0.90% (End of period vs. end of previous year) | -- | -- | | Owners' Equity Attributable to Shareholders (CNY) | 1,408,899,688.08 | 1.10% (End of period vs. end of previous year) | -- | -- | [Non-recurring Gains and Losses and Amounts](index=2&type=section&id=%28%E4%BA%8C%29%20%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) The company's non-recurring gains and losses totaled **2.02 million CNY** YTD, primarily from government grants, fair value changes, and other non-operating income/expenses, with a negative impact from non-current asset disposal losses YTD Non-recurring Gains and Losses and Amounts | Item | YTD Amount (CNY) | | :--- | :--- | | Disposal gains/losses of non-current assets | -2,948,849.14 | | Government grants recognized in current profit/loss | 4,626,555.73 | | Gains/losses from changes in fair value and investment income from disposal of financial assets | 1,535,012.12 | | Reversal of impairment provisions for receivables | 807,472.00 | | Other non-operating income and expenses | 2,781,075.96 | | Less: Income tax impact | 762,961.86 | | Minority interests impact (after tax) | 4,015,480.35 | | **Total** | **2,022,824.46** | [Analysis of Changes in Key Accounting Data and Financial Indicators](index=3&type=section&id=%28%E4%B8%89%29%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%8E%9F%E5%9B%A0) This section analyzes changes in major balance sheet, income statement, and cash flow statement items, reflecting the company's dynamics in debt repayment, receivables management, business growth, and project investments [Changes in Major Balance Sheet Items](index=3&type=section&id=1%E3%80%81%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8%E4%B8%BB%E8%A6%81%E9%A1%B9%E7%9B%AE%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5%E5%8F%8A%E5%88%86%E6%9E%90) Major Balance Sheet Item Changes (September 30, 2023 vs December 31, 2022) | Item | Change Percentage | Reason for Change | | :--- | :--- | :--- | | Monetary Funds | -36.13% | Repayment of related party and bank loans, payment for engineering construction investments, etc | | Accounts Receivable | -34.37% | Strengthened customer collection management, actively urged payment for goods | | Receivables Financing | -97.97% | Subsidiaries used bank acceptance bills to pay for purchases or mature acceptances | | Prepayments | 211.94% | Increase in prepayments for materials | | Other Current Assets | 72.64% | Increase in input VAT credit | | Right-of-use Assets | 127.99% | New property leases | | Deferred Income Tax Assets | 46.93% | Increase in deductible temporary differences due to bad debt provisions | | Other Non-current Assets | -53.46% | Decrease in prepaid engineering costs | | Contract Liabilities | -61.15% | Decrease in advance receipts for goods | | Taxes Payable | -62.01% | Expiration of national deferred tax payment policies, increased tax payments | | Non-current Liabilities Due Within One Year | -67.49% | Repayment of maturing loans | | Other Current Liabilities | -69.76% | Decrease in output VAT corresponding to advance receipts for goods | | Lease Liabilities | 108.79% | New property leases | | Provisions | -31.15% | Decrease in accrued sales rebates and payment of litigation compensation | | Deferred Income | 44.69% | Subordinate companies received government grants for project construction | | Other Comprehensive Income | 86.87% | Exchange rate changes leading to foreign currency statement translation differences | [Changes in Major Income Statement Items](index=3&type=section&id=2%E3%80%81%E5%88%A9%E6%B6%A6%E8%A1%A8%E4%B8%BB%E8%A6%81%E9%A1%B9%E7%9B%AE%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5%E5%8F%8A%E5%88%86%E6%9E%90) Major Income Statement Item Changes (January-September 2023 vs January-September 2022) | Item | Change Percentage | Reason for Change | | :--- | :--- | :--- | | Operating Revenue | 34.93% | Sales volume and prices of blood products such as human albumin and IVIG increased year-on-year | | Administrative Expenses | 37.00% | Resumption of work and production at Langfang Bohui, increased material consumption and losses | | Financial Expenses | -39.17% | Decrease in interest expenses due to reduced short-term debt | | Other Income | 42.04% | Increased government subsidies received year-on-year | | Credit Impairment Losses | 360.78% | Increase in bad debt provisions due to increased long-aged receivables | | Asset Impairment Losses | 3238.48% | Provision for inventory depreciation for some slow-moving products | | Gains/Losses from Disposal of Assets (Losses indicated by "-") | 388.01% | Increase in losses from disposal of fixed assets | | Non-operating Income | 1454.03% | Unpayable accounts payable transferred to non-operating income | | Income Tax Expense | 179.98% | Increase in income tax payable due to increased profitability of subsidiaries | [Changes in Major Cash Flow Statement Items](index=4&type=section&id=3%E3%80%81%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8%E4%B8%BB%E8%A6%81%E9%A1%B9%E7%9B%AE%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5%E5%8F%8A%E5%88%86%E6%9E%90) Major Cash Flow Statement Item Changes (January-September 2023 vs January-September 2022) | Item | Change Percentage | Reason for Change | | :--- | :--- | :--- | | Cash received from sales of goods and provision of services | 35.03% | Revenue growth and strengthened customer collection management | | Tax refunds received | -100.00% | Input tax credit refunds in the prior period, none in the current period | | Taxes and surcharges paid | 190.14% | Significant revenue growth, subsidiaries paid land transfer related taxes, paid deferred taxes from prior period | | Cash received relating to other investing activities | -96.92% | Input tax credit refunds in the prior period, none in the current period | | Cash paid for acquisition of fixed assets, intangible assets and other long-term assets | 30.46% | Increased expenditures for Yunnan blood product project, Langfang Bohui resumption of work, and establishment of new plasma stations | | Cash paid relating to other investing activities | -100.00% | No bank wealth management business in the current period | | Cash received from absorbing investments | -100.00% | Subsidiaries absorbed minority shareholder investments in the prior period, none in the current period | | Cash paid for repayment of debts | 50.60% | Increased repayment of bank loans | | Cash paid for distribution of dividends, profits or interest payments | 111.68% | Increased interest payments on bank loans | | Cash paid relating to other financing activities | -35.84% | Decreased repayment of related party loans | | Effect of exchange rate changes on cash and cash equivalents | -32377.17% | Foreign currency exchange rate differences | Shareholder Information [Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=5&type=section&id=%28%E4%B8%80%29%20%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the end of the reporting period, the company had **38,270 common shareholders**, with Du Jiangtao and his related parties holding a significant combined stake, and Du Jiangtao as the largest shareholder with **39.03%** - The total number of common shareholders at the end of the reporting period was **38,270**[15](index=15&type=chunk) Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held (shares) | Number of Restricted Shares Held (shares) | | :--- | :--- | :--- | :--- | :--- | | Du Jiangtao | Domestic Natural Person | 39.03% | 318,811,388 | 0 | | Hao Hong | Domestic Natural Person | 12.59% | 102,809,951 | 0 | | Yang Qi | Domestic Natural Person | 3.09% | 25,274,802 | 0 | | Du Jianghong | Domestic Natural Person | 3.00% | 24,478,560 | 18,358,920 | | Mei Yingjun | Domestic Natural Person | 1.94% | 15,827,755 | 0 | | Hong Kong Securities Clearing Company Limited | Overseas Legal Person | 0.94% | 7,647,302 | 0 | | He Xiaoyu | Domestic Natural Person | 0.85% | 6,959,818 | 0 | | Lu Yang | Domestic Natural Person | 0.61% | 5,000,000 | 0 | | Gu Chunyu | Domestic Natural Person | 0.54% | 4,400,100 | 0 | | Liu Hepu | Domestic Natural Person | 0.35% | 2,836,245 | 0 | - Among the top ten shareholders, Du Jiangtao and Hao Hong are a married couple, and Du Jiangtao and Du Jianghong are siblings, indicating an associated relationship[15](index=15&type=chunk) [Changes in Restricted Shares](index=5&type=section&id=%28%E4%B8%89%29%20%E9%99%90%E5%94%AE%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, restricted shareholdings of executives Zhang Lei and Niu Shuhui changed, with Niu Shuhui releasing **178,500 shares** and Zhang Lei adding **285,663 shares**, resulting in a slight increase in total restricted shares Changes in Restricted Shares (Unit: shares) | Shareholder Name | Beginning Restricted Shares | Shares Released in Current Period | Shares Added in Current Period | Ending Restricted Shares | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | :--- | | Zhang Lei | 856,989 | 0 | 285,663 | 1,142,652 | Executive Lock-up Shares | | Zhai Xiaofeng | 245,858 | 0 | 0 | 245,858 | Executive Lock-up Shares | | Niu Shuhui | 716,362 | 178,500 | 288 | 538,150 | Executive Lock-up Shares | | Du Jianghong | 18,358,920 | 0 | 0 | 18,358,920 | Executive Lock-up Shares | | Hu Lanlan | 2,091 | 0 | 0 | 2,091 | Executive Lock-up Shares | | **Total** | **20,180,220** | **178,500** | **285,951** | **20,287,671** | -- | Other Important Matters [Guaranteed Credit Limits and Progress](index=6&type=section&id=1%E3%80%81%E5%85%AC%E5%8F%B8%E7%AC%AC%E4%B8%83%E5%B1%8A%E8%91%A3%E4%BA%8B%E4%BC%9A%E7%AC%AC%E4%BA%8C%E5%8D%81%E4%B8%89%E6%AC%A1%E4%BC%9A%E8%AE%AE%E3%80%812022%20%E5%B9%B4%E5%BA%A6%E8%82%A1%E4%B8%9C%E5%A4%A7%E4%BC%9A%EF%BC%8C%E5%AE%A1%E8%AE%AE%E9%80%9A%E8%BF%87%E4%BA%86%E3%80%8A%E5%85%B3%E4%BA%8E%202023%20%E5%B9%B4%E5%BA%A6%E6%8B%85%E4%BF%9D%E9%A2%9D%E5%BA%A6%E9%A2%84%E8%AE%A1%E7%9A%84%E8%AE%AE%E6%A1%88%E3%80%8B) The company's board and shareholders approved a **1.2 billion CNY** credit guarantee limit for controlling subsidiaries in 2023, with **186 million CNY** in receivables guarantee provided for Hebei Bohui's plasma stations to Zheshang Bank during the reporting period - The company approved providing credit guarantees for Hebei Bohui, Inner Mongolia Bohui, and Guangdong Weilun from banks and other financial institutions, with a total amount not exceeding **1.2 billion CNY**[18](index=18&type=chunk) - In July 2023, the company signed 7 "Receivables Confirmation Agreements" with Zheshang Bank, providing guarantees for the transfer of **186 million CNY** in receivables from 6 plasma stations under Hebei Bohui[18](index=18&type=chunk) Quarterly Financial Statements [Consolidated Balance Sheet](index=6&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of September 30, 2023, the company's total assets were **3.87 billion CNY**, a slight decrease from the beginning of the year, with total current assets at **1.05 billion CNY** and non-current assets at **2.83 billion CNY** Consolidated Balance Sheet Key Data (September 30, 2023 vs January 1, 2023) | Item | September 30, 2023 (CNY) | January 1, 2023 (CNY) | | :--- | :--- | :--- | | Total Assets | 3,872,849,081.89 | 3,908,002,277.01 | | Total Current Assets | 1,046,321,438.84 | 1,140,130,256.34 | | Total Non-current Assets | 2,826,527,643.05 | 2,767,872,020.67 | | Total Liabilities | 1,533,317,733.85 | 1,584,123,343.91 | | Total Current Liabilities | 989,945,179.47 | 1,122,836,561.25 | | Total Non-current Liabilities | 543,372,554.38 | 461,286,782.66 | | Total Owners' Equity | 2,339,531,348.04 | 2,323,878,933.10 | | Total Owners' Equity Attributable to Parent Company | 1,408,899,688.08 | 1,393,532,991.70 | [Consolidated Income Statement from Year-Beginning to End of Reporting Period](index=9&type=section&id=2%E3%80%81%E5%90%88%E5%B9%B6%E5%B9%B4%E5%88%9D%E5%88%B0%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E5%88%A9%E6%B6%A6%E8%A1%A8) As of September 30, 2023, the company's total operating revenue reached **806.10 million CNY**, a **34.93%** increase year-on-year, achieving a net profit of **14.42 million CNY** from a prior-year loss Consolidated Income Statement Key Data (January-September 2023 vs January-September 2022) | Item | January-September 2023 (CNY) | January-September 2022 (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 806,104,920.39 | 597,413,453.96 | | Total Operating Costs | 772,229,494.76 | 679,084,214.56 | | Operating Profit | 30,320,163.13 | -79,895,791.55 | | Total Profit | 29,682,240.40 | -82,851,670.84 | | Income Tax Expense | 15,259,355.81 | 5,450,161.37 | | Net Profit | 14,422,884.59 | -88,301,832.21 | | Net Profit Attributable to Parent Company Shareholders | 14,137,166.03 | -39,318,798.46 | | Minority Interest Income/Loss | 285,718.56 | -48,983,033.75 | | Total Comprehensive Income | 15,652,414.94 | -84,160,488.27 | | Basic Earnings Per Share | 0.0173 | -0.0481 | [Consolidated Cash Flow Statement from Year-Beginning to End of Reporting Period](index=11&type=section&id=3%E3%80%81%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8%E4%B8%BB%E8%A6%81%E9%A1%B9%E7%9B%AE%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5%E5%8F%8A%E5%88%86%E6%9E%90) As of September 30, 2023, net cash flow from operating activities was **103.62 million CNY**, a significant improvement, while investing activities resulted in a net outflow of **150.80 million CNY**, and financing activities generated a net inflow of **3.56 million CNY** Consolidated Cash Flow Statement Key Data (January-September 2023 vs January-September 2022) | Item | January-September 2023 (CNY) | January-September 2022 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 103,617,734.96 | -28,327,997.49 | | Net Cash Flow from Investing Activities | -150,795,903.23 | -70,479,138.29 | | Net Cash Flow from Financing Activities | 3,563,270.52 | 161,112,292.32 | | Net Increase in Cash and Cash Equivalents | -44,169,258.18 | 62,306,874.04 | | Cash and Cash Equivalents at End of Period | 63,634,797.87 | 96,772,123.51 | [Accounting Standards and Audit Status](index=13&type=section&id=%E4%BC%9A%E8%AE%A1%E5%87%86%E5%88%99%E4%B8%8E%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) The company did not adopt new accounting standards for the first time in 2023, and this quarterly report remains unaudited - The company did not adjust financial statements at the beginning of the first execution year for new accounting standards starting in 2023[30](index=30&type=chunk) - The company's third-quarter report is unaudited[30](index=30&type=chunk)

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-048 北京博晖创新生物技术集团股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、审议通过《2023 年第三季度报告》 同意公司根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所创 业板上市公司第 47 号——上市公司季度报告公告格式》等法律、法规的相关要 求，结合本公司 2023 年第三季度的实际经营管理情况编制的《2023 年第三季度 报告》。该报告未经会计师事务所审计。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第三次会议于 2023 年 10 月 27 日在公司会议室召开，会议通知于 2023 年 10 月 17 日以专人送达、邮件通知或电话通知的方式送达各位董事，会 议由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本 次会议应出席董事 7 人，实际出席董事 7 人，监事和高级管理人员列席了会议。 本次会议的召集召开程序符合《公司法》和《公司章程 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-049 北京博晖创新生物技术集团股份有限公司 第八届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第三次会议于 2023 年 10 月 27 日在公司会议室召开，会议通知于 2023 年 10 月 17 日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司 监事会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议 应出席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和 《公司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2023 年第三季度报告》 监事会认为：公司结合 2023 年第三季度的实际经营管理情况编制的《2023 年 第三季度报告》符合《深圳证券交易所创业板股票上市规则》、《上市公司信息披露 管理办法》等法律、法规的相关要求。其内容真实、准确、完整的反映了公 ...

Group 1: Company Overview - The company was listed on May 23, 2012, and has two main business segments: inspection and testing services, and blood products [2] - The inspection and testing business has maintained stable revenue in recent years, while blood products have become a key area of development since entering the sector in 2015 [2] Group 2: Blood Plasma Collection - The company currently operates 15 plasma collection stations, with 6 in Yunnan, 2 in Inner Mongolia, and 1 in Shandong, among others [2] - In the first half of 2023, the company collected approximately 202 tons of plasma, with an expectation to exceed 400 tons for the entire year [2] Group 3: Production Capacity and Projects - The designed production capacity for the Yunnan blood product project is 1,500 tons of raw plasma per year, while the Inner Mongolia factory is designed for 800-1,000 tons [3] - The Yunnan project has completed construction and equipment installation, but the official operation date is pending government approval for production qualification [3] Group 4: Product Development and Market Position - The company is developing new products, including "Human Coagulation Factor VIII," which is in clinical stages, and "Human Fibrinogen," which is under research [3] - The company’s blood product revenue is currently lower than industry peers due to processing capacity constraints, with existing facilities operating at full capacity [3]

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 526.91 million, representing a 37.46% increase compared to CNY 383.31 million in the same period last year[24]. - The net profit attributable to shareholders was CNY 5.93 million, a significant turnaround from a loss of CNY 19.78 million in the previous year, marking a 129.96% increase[24]. - The net cash flow from operating activities reached CNY 80.39 million, a remarkable increase of 499.75% compared to a negative cash flow of CNY 20.11 million in the same period last year[24]. - The basic earnings per share improved to CNY 0.0073, compared to a loss of CNY 0.0242 per share in the previous year, reflecting a 130.17% increase[24]. - The total assets at the end of the reporting period were CNY 3.88 billion, a slight decrease of 0.61% from CNY 3.91 billion at the end of the previous year[24]. - The net assets attributable to shareholders increased by 0.52% to CNY 1.40 billion from CNY 1.39 billion at the end of the previous year[24]. - The weighted average return on net assets improved to 0.42%, up from -2.05% in the previous year[24]. - The company reported a net profit excluding non-recurring gains and losses of CNY 5.22 million, compared to a loss of CNY 21.26 million in the same period last year, representing a 124.57% increase[24]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 15% year-over-year growth[45]. - The company has outlined a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 1.32 billion RMB[45]. Business Segments - The company's main business segments include inspection testing and biological products[32]. - In the reporting period, the inspection testing business generated revenue of 133.75 million yuan, a decrease of 0.3% year-on-year[37]. - Revenue from in vitro diagnostic products was 85.02 million yuan, down 1.84% compared to the previous year[37]. - Revenue from non-medical testing products increased by 2.5% to 48.73 million yuan[37]. - The company’s main medical testing products include human trace element testing and HPV testing, targeting hospitals and third-party testing institutions[38]. Product Development and Innovation - The company is focused on expanding its product line in the medical device sector, particularly in immunoassay and atomic absorption technologies[40]. - The company is investing in R&D for advanced diagnostic technologies, with a focus on quantum dot fluorescence immunoassay methods, aiming to enhance testing accuracy and efficiency[46]. - The company is developing a nucleic acid chip detection instrument (Class II) for qualitative detection of 24 types of human papillomavirus, with a registration valid until November 26, 2028[42]. - The company has a new product for detecting respiratory viruses (Class III), which is intended for qualitative detection of influenza A and B viruses, with a registration expiring on February 28, 2026[42]. - The company’s total IgE antibody testing kit is expected to be launched by July 27, 2027, utilizing quantum dot immunofluorescence technology[48]. - The company is developing a fully automated nucleic acid detection analysis system, expected to be registered by May 30, 2028, for qualitative detection of target nucleic acids[48]. Market Expansion and Strategy - Market expansion plans include entering three new international markets by the end of 2024, targeting a 25% increase in international sales[45]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 200 million RMB allocated for potential mergers and acquisitions in 2024[45]. - The company aims to increase its market share in the diagnostic sector by 5% over the next year through aggressive marketing strategies and partnerships[45]. - The company is actively pursuing market expansion, with plans to enter three new provinces by Q4 2023, aiming for a 10% market share in these regions[172]. Quality Management and Compliance - The company has not identified any significant risk factors that could adversely affect its operational, financial, or profitability status[4]. - The company emphasizes quality management, having achieved certifications for medical device GMP, ISO13485, and ISO9001, ensuring high-quality product supply[64]. - The company has established a comprehensive quality management system to mitigate potential risks related to product safety, particularly in blood products[97]. Environmental Responsibility - The company is committed to sustainability and environmental responsibility, as evidenced by its ongoing projects and compliance with environmental regulations[138]. - The company has a wastewater treatment capacity of 400 tons per day, utilizing a comprehensive treatment process including neutralization, sedimentation, A/O, MBR, and disinfection with hypochlorous acid[143]. - The company has implemented upgrades to its wastewater treatment facilities, enhancing compliance with environmental regulations[136]. - The company has established internal wastewater treatment facilities to handle industrial wastewater generated during operations[140]. - The company has a monitoring system for wastewater with various parameters, including a maximum limit of 500 mg/L for fecal coliform bacteria, monitored quarterly[157]. Shareholder and Governance Matters - The annual shareholders' meeting had a participation rate of 45.47% on June 29, 2023[105]. - No cash dividends or stock bonuses were distributed for the half-year period, and no capital reserve was converted into share capital[108]. - The company appointed new directors and management on June 29, 2023, including a new chairman and several non-independent directors[106]. - The company has maintained a clean record with no significant litigation or arbitration matters reported in the first half of 2023[179]. Financial Management - The company has no significant related party transactions during the reporting period, ensuring transparency in operations[181][183]. - The company has no significant guarantees or collateral obligations reported, maintaining a conservative financial position[195]. - The company reported a total of 30 million yuan in claims related to a lawsuit that is still in the filing stage[184]. - The company has ongoing significant contracts that may impact its financial performance[200].

北京博晖创新生物技术集团股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | | 资金占用方名称 | 占用方与上市 | 上市公司核算的 | 2023 | 年期初占用资 | 2023 年 | 1-6 月份占用 | 2023年1-6月份占用 | | 2023年1-6月份偿 | 2023 年 | 6 月期 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 公司的关联关 | 会计科目 | | 金余额 | | 累计发生金额（不含利 | 资金的利息（如有） | | 还累计发生金额 | 末占用资金余 | | 因 | | | | | 系 | | | | | 息） | | | | 额 | | | | | 控股股东、实际控制人 | - | - | - | | - | | - | - | | - | - | | | | | 及其附属企业 | | - | - | | - | | - | - | | ...